Brind.
  1. AbbVie's Humira is facing steep competition from Omvoh in the market.
  2. Declining sales of Humira due to biosimilar erosion.

Lost patent protection for Humira in the US on August 20, 2025.

11 reports, 5 independent Updated Sep 24
Mostly repetition Reached 2 outlets in its first 24 hours
Reports
11
Developments
3
Repetition
73%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 5 independent outlets

Lost patent protection for Humira in the US on August 20, 2025.

Who's involved

What this event is mainly about

How it developed

Newest first. Tap a step to see who reported it.
  1. AbbVie successfully hurdled the patent cliff for Humira.1 source
  2. Revenue decline follows the loss of patent protection for Humira.1 source
  3. Loss of patent protection for Humira in the US.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • fool.com
  • aol.com
  • yahoo.comWhy Wall Street Can't Get Enough of This Dividend King
  • yahoo.com
  • ZacksAbbVie Rises 11.5% in a Month: Buy, Hold or Sell the Stock? AbbVie’s ABBV stock has risen 11.5% in the past month, mainly due to its beat-and-raise performance in the second quarter. AbbVie announced
  • Motley FoolThe 3 Things That Matter for AbbVie Now AbbVie's pair of immunology drugs is expected to help drive growth into the next decade. The company should successfully improve its lineup thanks to its deep
  • ZacksHere's How to Play AbbVie Stock as it Reaches Golden Cross AbbVie’s ABBV stock has been trading above its 50-day and 200-day simple moving averages (SMAs) since early July. The 50-day moving average
  • Unknown outlet
3 more outlets ran the same wire story